We have access to serum samples via my mentor Jean-Frederic Colombel -- who is the PI [principal investigator] of the PREDICTS study-- up to 10 years before Crohn's disease or ulcerative colitis ...

Addressing all aspects of healthcare maintenance in ulcerative colitis (UC) — one of two major types of inflammatory bowel ...

Notable news about inflammatory bowel disease (IBD) in 2024 included a study evaluating loss of response to tumor necrosis ...

New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion+), Crohn’s Disease ($2.5 billion+), ...

July 17, 2023 — Chronic inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis, is on the rise worldwide. The benefits of current medications are limited by problematic ...

The prevalence of inflammatory bowel disease in U.S. children under 20 is increasing, with over 100,000 affected, revealing ...

Microscopic colitis diseases are unusual and possibly autoimmune. They are sometimes triggered by medications and treated ...

By understanding more about the cycle of inflammation, it might be possible to find new ways to prevent or treat this in IBD.

A groundbreaking study published today in Gastroenterology provides the most comprehensive assessment to date of pediatric inflammatory bowel disease (IBD) prevalence in the United States.

Prevalence and Market Potential in Europe GERD, Crohn’s Disease and Ulcerative Colitis represent significant worldwide healthcare challenges across Europe. GERD: The GERD treatment market in ...

New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion+), Crohn’s Disease ($2.5 billion+), and Ulcerative Colitis ($1.9 billion+ ...

New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion+), Crohn’s Disease ($2.5 billion+), and Ulcerative Colitis ($1.9 billion+) The company ...